NICE has also recommended evolocumab as an option for treating primaryhypercholesterolaemia or mixed dyslipidaemia, only if:
• The dosage is 140 mg every 2 weeks.• Low-density lipoprotein concentrations are persistently above thresholds stipulated despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia).• The company provides evolocumab with the discount agreed in the patient access scheme.